Sun Pharma is expected to report modest Q2 FY26 earnings growth, with PAT likely up 2% YoY and revenue rising 7%. Analysts cite Leqselvi launch costs, weak Taro performance, and high R&D spend as ...
Orkla India IPO GMP, Allotment Status Live Updates: The allotment of Orkla India IPO shares was finalised on November 3, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback